Seraxis Inc

07/16/2023 | Press release | Archived content

Late-Breaking Results of a Preclinical Efficacy Study presented at ENDO 2023 show Seraxis SRE Sustainably Reverses Type-1-Diabetes Hyperglycemia.

Seraxis Inc published this content on July 16, 2023, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 17, 2026 at 10:27 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]